Reproducibility Meets Simplicity: Quansys Launches Q-View Imager Plus for ELISA

Published: 01 Aug 2025

Author: Precedence Research

Share :

Quansys Biosciences, a leading developer of multiplex immunoassay technology in the world, has released its most sophisticated laboratory imaging system, the Q-View Imager Plus. Allowing researchers to run reproducible high-resolution ELISA, this next-generation device will change the way academic, biopharmaceutical, and clinical research labs run and analyze immunoassay data. This launch is accompanied by a substantial revision to Q-View Software, including the format of an easier format and a higher level of analysis. The hardware-software pair, in combination, constitutes a complete solution that makes the complex lifeworkflows easier to handle and increases the quality of data, regulatory assessment, and scientific trustworthiness.

The Q-View Imager Plus has at its core a 35-megapixel multi-camera system with temperature-controlled sensors to guarantee consistent image acquisition of each well plate and in high-throughput settings. The Q-View IMager Plus is capable of displaying all the well plates simultaneously. The increasing workloads placed on laboratories in need of more rapidly analyzable and regulation-ready data pose a problem that the Imager Plus has answered with a powerful device that supports research-based as well as clinical-grade performance. Labs now reach a reproducibility and accuracy of results that pass the test of peer-reviewed-publication written records and FDA/CLIA grade controls with increased use of active cooling systems, ensured by improved image fidelity.

Imager Plus can also support advanced image analysis applications, including the integration of Imager Plus with digital pathology or protein expression profiling, which is important in biomarker discovery and translational medicine. The researchers can also record and store high-resolution images, allowing them to be analyzed again, documented, and shared among institutions. Flexibility and forward compatibility with evolving demands of scientific research ensure that Q-View Imager Plus will continue to grow as multiplexing and high-content assays take their place in drug development, immunology, and personalized medicine.

Executive’s Statement:

Adam Brown, CEO of Quansys Biosciences, emphasized the company’s mission during the launch: “We designed the Q-View Imager Plus and its upgraded Q-View Software to provide labs with consistent, high-quality data. By combining advanced imaging with powerful and intuitive analysis tools, we’ve delivered on our commitment to empowering labs with technologies that simplify complex workflows and deliver high-impact results, faster.’